STUDY PROTOCOL

Effect of internet-delivered cognitive behavioral therapy on insomnia in convalescent patients with COVID-19: Protocol for a systematic review and meta-analysis

Yan Chen¹, Xiang Zhou², Jie Liu³, Rui Li¹, Zihan Jiang¹, Lina Wang³, Shuya Wang³, Bo Li¹*

¹ Institute of Chronic Disease Risks Assessment, School of Nursing and Health, Henan University, Kaifeng, Henan, China, 2 Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China, 3 Huaihe Hospital of Henan University, Kaifeng, Henan, China

* 10210022@vip.henu.edu.cn

Abstract

Introduction

Coronavirus Disease 2019 (COVID-19) has made a serious public health threat worldwide. Recent evidence has indicated that COVID-19 patients in convalescence frequently experience insomnia, which reduces their quality of life and causes unknown risks. The positive effect of cognitive behavior on insomnia has been well addressed in previous studies. Given the high infectivity and epidemicity of COVID-19, Internet-delivered intervention may be safer than face-to-face treatment. However, whether Internet-delivered cognitive behavioral therapy can effectively improve the insomnia of COVID-19 patients in convalescence has not been completely determined yet. Therefore, we conducted a meta-analysis and systematic review to evaluate the effects of Internet-delivered cognitive behavioral therapy on insomnia in COVID-19 patients in convalescence, with the aim to confer some guidance for its clinical application.

Methods and analysis

This systematic review and meta-analysis has been registered in the International Prospective Register of Systematic Reviews (PROSPERO). Two researchers will retrieve the relevant literature on Internet-delivered cognitive behavioral therapy for insomnia in convalescent patients with COVID-19 in PubMed, Web of Science, Embase, MEDLINE, Cochrane Library, Clinical Trials gov, Chinese Biomedical Literature Database (CBM), and Chinese National Knowledge Infrastructure (CNKI) from inception to 11th of December. In addition, we will review the relevant trials and references of the included literature and manually searched the grey literature. The two researchers will independently extracted data and information and evaluated the quality of the included literature. The Review Manager software (version 5.3) and Stata software (version 14.0) will be used for data analysis. The
mean difference or the standardized mean difference of 95% CI will be used to calculate continuous variables to synthesize the data. In addition, $\hat{I}^2$ and Cochrane will be used for heterogeneity assessment.

**Trial registration**

PROSPERO registration number CRD42021271278.

**Funding:** The authors received no specific funding for this work.

**Competing interests:** The authors have declared that no competing interests exist.

**Introduction**

World Health Organization (WHO) has reported that the ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected 200,840,180 people and resulted in 4,265,903 deaths worldwide by 6th August 2021 [1]. COVID-19 has rapidly developed into a pandemic and seriously threatened public health all over the world [2, 3]. COVID-19 pandemic seriously jeopardizes human physical and mental health [4] and attracts the concerns of numerous researchers [5]. The exploration of novel prevention, diagnosis, and treatment strategies has become a hot topic among scholars [6, 7], but little attention is paid to the mental health of COVID-19 patients in convalescence [8]. Studies have shown that the confirmed patients with COVID-19 tend to experience various psychological disorders such as stress, anxiety, depression, irritability, depression, and despair [9, 10]. Even though the mood of patients recovering from COVID-19 infection has improved, their symptoms of insomnia and fatigue still persist [11]. A considerable number of patients still suffer from insomnia and other symptoms of sleep disorders in the convalescent period [12]. A prospective cohort and nested case-control study has revealed that 29.17% of COVID-19 patients in convalescence experience insomnia [13].

Insomnia is defined as difficulties in falling asleep, maintaining asleep, or waking up too early at least three times per week for at least 3 months [14] and is one of the most common problems experienced by convalescent patients with COVID-19 [13]. COVID-19-related worries and loneliness are the major contributors to clinical insomnia in addition to education status, virus infection, and pre-existing mental health disorders [14, 15]. Poor sleep quality leads to adverse outcomes of physical [16] and mental health [17]. If left untreated, insomnia can aggravate anxiety, depression, and post-traumatic stress disorder and eventually compromise the quality of life [18]. Moreover, severe insomnia disorder or irregular sleep-wake cycle may damage the immune system and inflammatory response and increase the susceptibility to virus infection [19].

At present, primary health care and outpatient mental health institutions are responsible for the treatment of insomnia [20]. Drug therapy remains the most commonly used intervention method for insomnia. Despite the rapid curative effects, drug therapy fails to achieve radical treatment and also results in many adverse reactions [21–23]. Cognitive behavioral therapy, as an evidence-based option, has been found to effectively improve sleep outcomes [24, 25] and its therapeutic effect is equivalent to or better than that of drug therapy [26]. Since SARS-CoV-2 spreads through close contact between people [27], keeping a distance of more than two meters and using an N-95 mask are the most effective ways to prevent the spread of COVID-19 [28]. Under the guidance of therapists, the effect of Internet-delivered cognitive behavioral therapy on some mental and physical diseases is equivalent to that of face-to-face cognitive behavioral therapy [29], because the possibility of novel coronavirus pneumonia reinfection is unknown [30]. As a kind of digital therapy, Internet-delivered cognitive
behavioral therapy provides patients with evidence-based treatment interventions, which are driven by software to prevent, manage, or treat medical disorders or diseases [31]. It can be used independently or in concert with medications, devices, or other therapies [31]. Internet-delivered cognitive behavioral therapy represents a promising option to solve the obstacles of psychotherapy [32], which overcomes several limits related to traditional clinical practice [33] and possesses the advantages of low cost [31], high efficiency [31], and continuous monitoring [33]. Therefore, the cognitive behavioral therapy provided by the Internet may also have potential advantages in improving the insomnia of COVID-19 patients in the convalescent period.

The existing studies have shown that Internet-delivered cognitive behavioral therapy can improve symptoms of insomnia in adults [34]. However, a recent study has also found that Internet-delivered cognitive therapy has no significant effect on improving the insomnia of COVID-19 patients [35]. Therefore, this protocol is established to determine the effectiveness of Internet-delivered cognitive behavioral therapy for relieving insomnia symptoms in newly recovered patients with COVID-19.

Review questions
Under the current COVID-19 epidemic background, can Internet-delivered cognitive therapy improve insomnia in rehabilitative patients?

Objectives
The main purpose of this study is to conduct a systematic review and meta-analysis through randomized controlled trials (RCTs) to determine whether the Internet-delivered cognitive behavioral therapy can relieve insomnia in convalescent patients with COVID-19, improve the sleep quality of convalescent patients with COVID-19, and then improve the psychological condition of these patients.

Materials and methods
The protocol is in line with the Preferred Reporting Items for Systematic Reviews and Meta-analysis for Protocol (PRISMA-P) [36].

Inclusion criteria of the study
This systematic review protocol includes the following studies:

Types of studies
We included randomized controlled trials (RCTs). These trials report the effects of Internet-delivered cognitive behavioral therapy on insomnia in convalescent patients with COVID-19.

Participants
Participants are COVID-19 patients with sleep disorders in the convalescent period. Mental disorders will be involved in the meta-analysis.

Ethics and dissemination
Since this study reviews the published data, ethical approval is not required. The results of this systematic review and meta-analysis will be published in peer-reviewed journals.
Interventions
The intervention group will receive Internet-delivered cognitive behavioral therapy. Internet-delivered cognitive behavioral therapy will be conducted under the guidance of experienced psychotherapists or trained therapists. Patients will log into a secure website to access, read, and download online materials organized in a series of lessons or modules, including cognitive reconstruction, loosening practice, knowledge explanation, health education, and so on.

Comparisons
Patients in the control group will receive routine care, such as self-regulation, medical consultation, and support.

Outcome indicators
The sleep indicators for COVID-19 patients in convalescence will be as follows: (1) sleep quality (SQ), (2) time in bed, (3) sleep time (ST), (4) sleep efficiency (SE), (5) sleep disturbance (SD), (6) daytime function (DF), (7) Pittsburgh Sleep Quality Index (PSQI), and (8) Insomnia Severity Index (ISI).

Search strategy
Two researchers (YC, XZ) will retrieve the relevant English and Chinese literature independently in the following databases from inception to 11th of December: PubMed, Web of Science, Embase, MEDLINE, Cochrane Library, ClinicalTrials.gov, Chinese Biomedical Literature Database (CBM), and Chinese National Knowledge Infrastructure (CNKI). PubMed literature search is as follows: (Table 1).

Literature selection and data extraction

Literature selection
The literature screening process will follow the steps in the PRISMA flow chart (Fig 1). Firstly, after retrieving all databases, we will use Endnote 9.0 software to eliminate duplicate studies. Then, the two researchers will independently examined the titles and abstracts of the documents obtained after weight removal and preliminarily screened the documents. Subsequently, the two researchers will independently read the preliminarily screened literature according to the inclusion and exclusion criteria we formulate in advance. Finally, the literature screened by the two researchers will be compared to determine the literature finally included in the analysis. A third independent researcher will be consulted to achieve a final consensus in case of disagreement between both researchers.

Data extraction
The extraction of data and information in the literature will be completed by two researchers independently, including first author, publication date, country, intervention implementer, sample number, sample age, sample source, intervention time of online cognitive behavioral therapy, intervention frequency, dropout rate, insomnia assessment tool, and other details. Data will be collected and analyzed in the near future.

Risk of bias assessment in the included literature
The two researchers will use the Cochrane bias risk assessment tool to independently assess the risk of publication bias of each included literature (random sequence generation,
random assignment concealment, blind method, incomplete result data, selective reporting bias, and other bias). The bias risk will include the risk of high, unclear, or low bias [37]. If there are any differences in the assessment, a third researcher will be consulted to resolve the dispute.

**Data synthesis and statistical analysis**

Review Manager 5.3 software and Stata 14.0 software will be used for quantitative data analysis, including overall forest mapping, heterogeneity analysis, subgroup analysis, sensitivity analysis, and funnel mapping. For the diverse insomnia assessment tools, the standardized mean difference (SMD) and its 95% confidence interval (CI) will be used to describe the size of the effect. On the contrary, the mean difference (MD) and 95% CI will be used to represent the size of the effect.
Assessment of heterogeneity

The heterogeneity assessment will be conducted using the Rev Man 5.3 software. The Chi-Squared test and $I^2$ will be adopted to examine the statistical heterogeneity of the included studies.
studies. The random-effect model \((P \leq 0.1 \text{ and } I^2 > 50\%)\) or fixed-effect model \((P > 0.1 \text{ and } I^2 \leq 50\%)\) will be selected according to the values of \(P\) and \(I^2\).

Subgroup analysis
When heterogeneity is found in the results, subgroup analysis will be performed on the basis of ensuring sufficient data. The criteria will include characteristics (such as country or sample source), study quality, type of control intervention, and duration. In addition, we will analyze any other subgroups reported in the literature.

Assessment of reporting bias
Publication bias will be assessed by visual inspection of the funnel plot asymmetry and Egger’s regression test [38].

Sensitivity analysis
The robustness of analysis results will be explored by sensitivity analysis. Sensitivity analysis will be performed by excluding each uncertain factor to determine the sensitive factor exerting an important impact on the overall results.

Quality of evidence
The researchers will assess the quality of evidence for the entire study in accordance with the Grades of Recommendation, Assessment, Development, and Evaluation system established by the WHO and international organizations. The GRADE system will rate the quality of evidence as “high,” “medium,” “low,” and “lowest” [39].

Discussion
Insomnia seriously impairs the quality of life of COVID-19 patients in convalescence and causes severe mental disorders such as anxiety, depression, and fear [40]. Therefore, the use of scientific psychological intervention to treat insomnia is of great practical significance. Previous studies have shown that Internet-delivered cognitive behavioral therapy can make insomnia patients achieve lasting sleep improvement over a period of time with fewer side effects [41]. Based on the existing evidence, we reasonably speculate that cognitive behavioral therapy can also relieve the insomnia of COVID-19 patients in convalescence.

Due to the impact of methodological quality, information bias, and adequacy of results reporting of the included literature, the therapeutic effect of Internet-delivered cognitive behavioral therapy on insomnia in COVID-19 patients in convalescence may be affected. Therefore, we need to conduct large-scale and high-quality research in the future to obtain more accurate results.

Supporting information
S1 Checklist. PRISMA-P 2009 checklist.
(DOC)
S1 Fig. Flow diagram of study selection process.
(DOCX)
Author Contributions
Conceptualization: Yan Chen, Rui Li, Zihan Jiang, Shuya Wang.
Data curation: Shuya Wang.
Formal analysis: Yan Chen, Shuya Wang.
Funding acquisition: Bo Li.
Methodology: Xiang Zhou.
Software: Xiang Zhou.
Supervision: Lina Wang.
Writing – review & editing: Yan Chen, Jie Liu, Zihan Jiang.

References
1. Dressel A, Mkandawire-Valhmu L. Celebrate World Health Day: Nursing and Global Health. J Contiu Educ Nurs. 2019; 50(4):145–147. https://doi.org/10.3928/00220124-20190319-02 PMID: 30942887
2. Jiang S, Du L, Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect. 2020; 9(1):275–277. https://doi.org/10.1080/22221751.2020.1723441 PMID: 32005086
3. Coronavirus Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5(4):536–544. https://doi.org/10.1038/s41564-020-0695-z PMID: 32123347
4. Majumder J, Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J. 2021; 23(1):14. https://doi.org/10.1208/s12248-020-00532-2 PMID: 33400058
5. Zhang S, Liu L, Yang B, Li R, Luo J, Huang J, et al. Clinical characteristics of 134 convalescent patients with COVID-19 in Guizhou, China. Respir Res. 2020; 21(1):314. https://doi.org/10.1186/s12931-020-01580-0 PMID: 33243228
6. Cohen MS, Corey L. Combination prevention for COVID-19. Science. 2020; 368(6491):551. https://doi.org/10.1126/science.abc5798 PMID: 32381692
7. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020; 30(3):313–324. https://doi.org/10.4014/jmb.2003.03011 PMID: 32238757
8. Liu HQ, Yuan B, An YW, Chen KJ, Hu Q, Hu XP, et al. Clinical characteristics and follow-up analysis of 324 discharged COVID-19 patients in Shenzhen during the recovery period. Int J Med Sci. 2021; 18(2):347–355. https://doi.org/10.7150/ijms.50873 PMID: 33390803
9. Guo Y, Cheng C, Zeng Y, Li Y, Zhu M, Yang W, et al. Mental Health Disorders and Associated Risk Factors in Quarantined Adults During the COVID-19 Outbreak in China: Cross-Sectional Study. J Med Internet Res. 2020; 22(8):e20328. https://doi.org/10.2196/20328 PMID: 32716999
10. Serafini G, Rihmer Z, Amerio A, Aguglia A, Amore M. COVID-19 infection and mental disorders: a call for action to enhance protection and break down barriers. Psychiatr Hung. 2020; 35(3):245–246. PMID: 32643615
11. Becker PM. Overview of sleep management during COVID-19. Sleep Med. 2021; 51:389–945(21) 00248-3. https://doi.org/10.1016/j.sleep.2021.04.024 PMID: 33975774
12. Pappa S, Ntella V, Giannakas T, Giannakoulis VG, Papoutsi E, Katsaounou P. Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis. Brain Behav Immun. 2020; 88:901–907. https://doi.org/10.1016/j.bbi.2020.05.026 PMID: 32437819
13. Li L, Gou CY, Li XM, Song WY, Wang XJ, Li HY, et al. Effects of Chinese Medicine on Symptoms, Syndrome Evolution, and Lung Inflammation Absorption in COVID-19 Convalescent Patients during 84-Day Follow-up after Hospital Discharge: A Prospective Cohort and Nested Case-Control Study. Chin J Integr Med. 2021; 27(4):245–251. https://doi.org/10.1007/s11655-021-3328-3 PMID: 33534076
14. Kwak A, Jacobs J, Haggett D, Jimenez R, Peppercorn J. Evaluation and management of insomnia in women with breast cancer. Breast Cancer Res Treat. 2020; 181(2):269–277. https://doi.org/10.1007/s10549-020-05635-0 PMID: 32314110
15. Kokou-Kpolou CK, Megalakaki O, Laimou D, Kousouri M. Insomnia during COVID-19 pandemic and lockdown: Prevalence, severity, and associated risk factors in French population. Psychiatry Res. 2020; 290:113128. https://doi.org/10.1016/j.psychres.2020.113128 PMID: 32563951

16. Itani O, Jike M, Watanabe N, Kaneita Y. Short sleep duration and health outcomes: a systematic review, meta-analysis, and meta-regression. Sleep Med. 2017; 32:246–256. https://doi.org/10.1016/j.sleep.2016.08.006 PMID: 27743803

17. Baglioni C, Nanovska S, Regen W, Spiegelhalder K, Feige B, Nissen C, et al. Sleep and mental disorders: A meta-analysis of polysomnographic research. Psychol Bull. 2016; 142(9):969–990. https://doi.org/10.1037/0234000053 PMID: 27416139

18. De Lorenzo R, Conte L, Lanzani C, Benedetti F, Roveri L, Mazza MG, et al. Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study. PLoS One. 2020; 15(10): e0239570. https://doi.org/10.1371/journal.pone.0239570 PMID: 33052920

19. Mello MT, Silva A, Guerreiro RC, da-Silva FR, Estevess AM, Poyares D, et al. Sleep and COVID-19: considerations about immunity, pathophysiology, and treatment. Sleep Sci. 2020; 13(3):199–209. https://doi.org/10.5935/1984-0063.20200062 PMID: 3381288

20. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia MJ. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008; 4(5):473–504. PMID: 18853708

21. Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract. 2012; 13:40. https://doi.org/10.1186/1471-2296-13-40 PMID: 22631616

22. Riemann D, Perlis ML. The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Med Rev. 2009; 13(3):205–14. https://doi.org/10.1016/j.smrv.2008.06.001 PMID: 19201632

23. Morin CM, Bootzin RR, Buysse DJ, Dorsey C, Sateia MJ. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998–2004). Sleep. 2006; 29(11):1389–414. https://doi.org/10.1093/sleep/29.11.1389 PMID: 17162986

24. Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015; 163(3):191–204. https://doi.org/10.7326/M14-2841 PMID: 26054060

25. Irwin MR, Cole JC, Nicassio PM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged and in older adults 55+ years of age. Health Psychol. 2006; 25(1):3–14. https://doi.org/10.1037/0278-6133.25.1.3 PMID: 16448292

26. Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002; 159(1):5–11. https://doi.org/10.1176/appi.ajp.159.1.5 PMID: 11772681

27. Cheng VCC, Wong SC, Chen JHK, Yip CCY, Chuang VWM, Tsang OTY, et al. Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong. Infect Control Hosp Epidemiol. 2020; 41(5):493–498. https://doi.org/10.1017/icke.2020.58 PMID: 32131908

28. Chu DK, Akh EA, Duda S, Solo K, Yaacoub S, Schünemann HJ. COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020; 395(10242):1973–1987. https://doi.org/10.1016/S0140-6736(20)31142-9 PMID: 32497510

29. Andersson G, Cuijpers P, Carbringer P, Riper H, Hedman E. Guided Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: a systematic review and meta-analysis. World Psychiatry. 2014; 13(3):288–95. https://doi.org/10.1002/wps.20151 PMID: 25273302

30. Wolaich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M, et al. Clinical Practice Guidance for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019; 144(4):e20192528. https://doi.org/10.1542/peds.2019-2528 PMID: 31570648

31. Abbadesa G, Brigo F, Clerico M, De Mercanti S, Troisi F, Tedeschi G, et al. Digital therapeutics in neurology. J Neurol. 2022; 269(3):1209–1224. https://doi.org/10.1007/s00415-021-10608-4 PMID: 34018047

32. Xiang X, Wu S, Zuverink A, Tomasino KN, An R, Himle JA. Internet-delivered cognitive behavioral therapies for late-life depressive symptoms: a systematic review and meta-analysis. Aging Ment Health. 2020; 24(8):1196–1206. https://doi.org/10.1080/13607863.2019.1590309 PMID: 30913898

33. Khirasra R, Singh V, Batta A. Exploring digital therapeutics: The next paradigm of modern health-care industry. Perspect Clin Res. 2020; 11(2):54–58. https://doi.org/10.4103/pcr.ePCR_03_19 PMID: 32670828
34. Seyffert M, Lagisetty P, Landgraf J, Chopra V, Pfeiffer PN, Conte ML, et al. Internet-Delivered Cognitive Behavioral Therapy to Treat Insomnia: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(2):e0149139. https://doi.org/10.1371/journal.pone.0149139 PMID: 26867139

35. Aminoff V, Sellén M, Sörliden E, Ludvigsson M, Berg M, Andersson G. Internet-Based Cognitive Behavioral Therapy for Psychological Distress Associated With the COVID-19 Pandemic: A Pilot Randomized Controlled Trial. Front Psychol. 2021; 12:684540. https://doi.org/10.3389/fpsyg.2021.684540 PMID: 34194374

36. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097 PMID: 19621072

37. Higgins JP, Altman DG, Getzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. https://doi.org/10.1136/bmj.d5928 PMID: 22008217

38. Irwig L, Macaskill P, Berry G, Glasziou P. Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased. BMJ. 1998; 316(7129): 470–1. PMID: 9492687

39. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64(4):383–94. https://doi.org/10.1016/j.jclinepi.2010.04.026 PMID: 21195583

40. Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, et al. COVID-19 BioB Outpatient Clinic Study group, Rovere-Querini P, Benedetti F. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun. 2021; 94:138–147. https://doi.org/10.1016/j.bbi.2021.02.021 PMID: 33639239

41. Zachariae R, Lyby MS, Ritterband LM, O’Toole MS. Efficacy of internet-delivered cognitive-behavioral therapy for insomnia—A systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2016; 30:1–10. https://doi.org/10.1016/j.smrv.2015.10.004 PMID: 26615572